Cyclosporine A: A Review of Current Oral and Intravenous Delivery Systems

REFERENCES

• Alangary A. A., Bayomi M. A., Khidr S. N., Almeshal M. A., Aldardiri M. Characterization, stability and in-vivo targeting of liposomal formulations containing cyclosporine. International Journal of Pharmaceutics 1995; 114(2)221–225
   Web of Science ®Google Scholar
• Aliabadi H. M., Mahmud A., Sharifabadi A. D., Lavasanifar A. Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of Cyclosporine A. Journal of Controlled Release 2005; 104(2)301–311
   PubMed Web of Science ®Google Scholar
• Andrysek I. Impact of physical properties of formulations on bioavailability of active substance: current and novel drugs with cyclosporine. Molecular Immunology 2003; 39(17–18)1061–1065
   PubMed Web of Science ®Google Scholar
• Atkinson K., Biggs J. C., Britton K. Distribution and persistence of cyclosporin in human tissues. The Lancet 1982; 320(8308)1165
   Google Scholar
• Bistrup C., Nielsen F. T., Jeppesen U. E., Dieperink H. Effect of grapefruit juice on Sandimmun Neoral (R) absorption among stable renal allograft recipients. Nephrology Dialysis Transplantation 2001; 16(2)373–377
   PubMed Web of Science ®Google Scholar
• Bohme M., Buchler M., Mueller M., Keppler D. Differential inhibition by cyclosporins of primary-active atp-dependent transporters in the hepatocyte canalicular membrane. Febs Letters 1993; 333(1–2)193–196
   PubMed Web of Science ®Google Scholar
• Borel J. F. The cyclosporins. Transplantation Proceedings 1989; 21(1)810–815
   PubMed Web of Science ®Google Scholar
• Calne R. Y., Thiru S., McMaster P., Craddock G. N., White D. J. G., Evans D. B., Dunn D. C., Pentlow B. D., Rolles K. Cyclosporin A in patients receiving renal allografts from cadaver donors. The Lancet 1978; 312(8104)1323–1327
   Google Scholar
• Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. Canadian Pharmacists Association, Ottawa 2006
   Google Scholar
• Chen G., Duran G. E., Steger K. A., Lacayo N. J., Jaffrezou J. P., Dumontet C., Sikic B. I. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. Journal of Biological Chemistry 1997; 272(9)5974–5982
   PubMed Web of Science ®Google Scholar
• Choice E., Masin D., Bally M. B., Meloche M., Madden T. D. Liposomal cyclosporine - comparison of drug lipid carrier pharmacokinetics and biodistribution. Transplantation 1995; 60(9)1006–1011
   PubMed Web of Science ®Google Scholar
• El Tayar N., Mark A. E., Vallst P., Brunne R. M., Testa B., van Gunsteren W. F. Sovent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. Journal of Medicinal Chemistry 1993; 36(24)3757–3764
   PubMed Web of Science ®Google Scholar
• Francis M. F., Cristea M., Yang Y. L., Winnik F. M. Engineering polysaccharide-based polymeric micelles to enhance permeability of cyclosporin a across Caco-2 cells. Pharmaceutical Research 2005; 22(2)209–219
   PubMed Web of Science ®Google Scholar
• Frei U., Taesch S., Niese D. Use of sandimmun-neoral in renal-transplant patients. Transplantation Proceedings 1994; 26(5)2928–2931
   PubMed Web of Science ®Google Scholar
• Freise C. E., Liu T., Hong K. L., Osorio R. W., Papahadjopoulos D., Ferrell L., Ascher N. L., Roberts J. P. The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome. Transplantation 1994; 57(6)928–932
   PubMed Web of Science ®Google Scholar
• Fricker G., Drewe J., Huwyler J., Gutmann H., Beglinger C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: In vitro in vivo correlation. British Journal of Pharmacology 1996; 118(7)1841–1847
   PubMed Web of Science ®Google Scholar
• Friis G. J., Bundgaard H. Kinetics of degradation of cyclosporine-A in acidic aqueous-solution and its implication in its oral absorption. International Journal of Pharmaceutics 1992; 82(1–2)79–83
   Web of Science ®Google Scholar
• Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. European Journal of Cancer 2001; 37(13)1590–1598
   PubMed Web of Science ®Google Scholar
• Hebert M. F. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Advanced Drug Delivery Reviews 1997; 27(2–3)201–214
   PubMed Web of Science ®Google Scholar
• Honcharik N., Yatscoff R. W., Jeffrey J. R., Rush D. N. The effect of meal composition on cyclosporine absorption. Transplantation 1991; 52(6)1087–1089
   PubMed Web of Science ®Google Scholar
• Hows J. M., Smith J. M. In vitro stability of cyclosporin A. Journal of Clinical Pathology 1983; 36(6)720–721
   PubMed Web of Science ®Google Scholar
• Jacobson P. A., Maksym C. J., Landvay A., Weiner N., Whitmore R. Compatibility of cyclosporine with fat emulsion. American Journal of Hospital Pharmacy 1993; 50(4)687–690
   PubMedGoogle Scholar
• Kahan B. D., Dunn J., Fitts C., Vanburen D., Wombolt D., Pollack R., Carson R., Alexander J. W., Choc M., Wong R., Hwang D. S. Reduced intersubject and intrasubject variability in cyclosporine pharmacokinetics in renal-transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59(4)505–511
   PubMed Web of Science ®Google Scholar
• Kahan B. D. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplantation Proceedings 2004; 36(2)378s–391s
   PubMed Web of Science ®Google Scholar
• Karlsson J., Fong K. S., Hansson M. J., Elmer E., Csiszar K., Keep M. F. Life span extension and reduced neuronal death after weekly intraventricular cyclosporin injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurosurgery 2004; 101(1)128–137
   PubMed Web of Science ®Google Scholar
• Lallemand F., Perottet P., Felt-Baeyens O., Kloeti W., Philippoz F., Marfurt J., Besseghir K., Gurny R. A water-soluble prodrug of cyclosporine A for ocular application: A stability study. European Journal of Pharmaceutical Sciences 2005; 26(1)124–129
   PubMed Web of Science ®Google Scholar
• Lechuga-Ballesteros D., Abdul-Fattah A., Stevenson C. L., Bennett D. B. Properties and stability of a liquid crystal form of cyclosporine - The first reported naturally occurring peptide that exists as a thermotropic liquid crystal. Journal of Pharmaceutical Sciences 2003; 92(9)1821–1831
   PubMed Web of Science ®Google Scholar
• Lee M. K., Choi L., Kim M. H., Kim C. K. Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles. International Journal of Pharmaceutics 1999; 191(2)87–93
   PubMed Web of Science ®Google Scholar
• Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Therapeutic Drug Monitoring 1991; 13(6)465–477
   PubMed Web of Science ®Google Scholar
• Mason J. Cyclosporins past, present, and future. Transplantation Proceedings 1992; 24(4)61–63
   PubMed Web of Science ®Google Scholar
• Molpeceres J., Aberturas M. R., Guzman M. Biodegradable nanoparticles as a delivery system for cyclosporine: preparation and characterization. Journal of Microencapsulation 2000; 17(5)599–614
   PubMed Web of Science ®Google Scholar
• Mueller E. A., Kovarik J. M., Vanbree J. B., Lison A. E., Kutz K. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal-allograft recipients - a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57(8)1178–1182
   PubMed Web of Science ®Google Scholar
• Mueller E. A., Kovarik J. M., Vanbree J. B., Tetzloff W., Grevel J., Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharmaceutical Research 1994; 11(2)301–304
   PubMed Web of Science ®Google Scholar
• Noble S., Markham A. Cyclosporin - a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral). Drugs 1995; 50(5)924–941
   PubMed Web of Science ®Google Scholar
• Novartis_Phamaceuticals_Canada. Prescribing Information: Neoral and Sandimmune I.V. 2004
   Google Scholar
• Novartis_Phamaceuticals_Corporation. Neoral Soft Gelatin Capsules and Oral Solution. 2005a; T2005-23: 1–35
   Google Scholar
• Novartis_Pharmaceuticals_Corporation. Sandimmune Soft Gelatin Capsules, Oral Solution and Injection. 2005b; T2005-44
   Google Scholar
• Ohashi R., Kamikozawa Y., Sugiura M., Fukada H., Yabwchi H., Tamai I. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metabolism and Disposition 2006; 34(5)793–799
   PubMed Web of Science ®Google Scholar
• Ouyang C., Choice E., Holland J., Meloche M., Madden T. D. Liposomal cyclosporine - characterization of drug incorporation and interbilayer exchange. Transplantation 1995; 60(9)999–1006
   PubMed Web of Science ®Google Scholar
• Pichard-Garcia L., Whomsley R., Davjat M., Maurel P., Setoyama T., Humphries T. J. Comparative effects of rabeprazole and omeprazole on the inducibility of cytochrome P450-1A and cytochrome P450-3A isoenzymes in human hepatocytes, and effects on cyclosporin metabolism in human liver microsomes. Clinical Drug Investigation 2000; 20(4)245–254
   Web of Science ®Google Scholar
• Powles R. L., Clink H., Sloane J., Barrett A. J., Kay H. E. M., McElwain T. J. Cyclosporin A for the treatment of graft‐versus-host disease in man. The Lancet 1978; 312(8104)1327–1331
   Google Scholar
• Ptachcinski R. J., Venkataramanan R., Burckart G. J. Clinical pharmacokinetics of cyclosporin. Clinical Pharmacokinetics 1986; 11: 107–132
   PubMed Web of Science ®Google Scholar
• Ptachcinski R. J., Venkataramanan R., Rosenthal J. T., Burckart G. J., Taylor R. J., Hakala T. R. The effect of food on cyclosporine absorption. Transplantation 1985; 40(2)174–176
   PubMed Web of Science ®Google Scholar
• Scheff S. W., Sullivan P. G. Cyclosporin A significantly ameliorates cortical damage following experimental traumatic brain injury in rodents. Journal of Neurotrauma 1999; 16(9)783–792
   PubMed Web of Science ®Google Scholar
• Seeballuck F., Ashford M. B., O'Driscoll C. M. The effects of Pluronic (R) block copolymers and Cremophor (R) EL on intestinal lipoprotein processing and the potential link with P‐glycoprotein in Caco-2 cells. Pharmaceutical Research 2003; 20(7)1085–1092
   PubMed Web of Science ®Google Scholar
• Sigma. Cyclosporin A Product Information 1996; C3667: 1–2
   Google Scholar
• Varela M. C., Guzman M., Molpeceres J., Aberturas M. D., Rodriguez-Puyol D., Rodriguez-Puyol M. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. European Journal of Pharmaceutical Sciences 2001; 12(4)471–478
   PubMed Web of Science ®Google Scholar
• Vonderscher J., Meinzer A. Rationale for the development of Sandimmune-Neoral. Transplantation Proceedings 1994; 26(5)2925–2927
   PubMed Web of Science ®Google Scholar
• Yonan N., Martyszczuk R., Machaal A., Baynes A., Keevil B. G. Monitoring of cyclosporine levels in transplant recipients using self-administered fingerprick sampling. Clinical Transplantation 2006; 20(2)221–225
   PubMed Web of Science ®Google Scholar
• Yoshikawa Y., Miyazaki M., Hovjou T., Komuta Y., Yoshikawo H., Takada K. Biodistribution of cyclosporin encapsulated in liposomes modified with bioadhesive polymer. Journal of Pharmacy and Pharmacology 1997; 49(7)661–668
   PubMed Web of Science ®Google Scholar
• Zhang Q. N., Yie G. Q., Li Y., Yang Q. S., Nagai Y. T. Studies on the cyclosporin A loaded stearic acid nanoparticles. International Journal of Pharmaceutics 2000; 200(2)153–159
   PubMed Web of Science ®Google Scholar